{"success":true,"data":{"pressRelease":{"id":"134558","rtpr_id":"nPn3J2XFJa","ticker":"3696","exchange":"HKEX","all_tickers":["3696"],"title":"Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain","author":"PR Newswire","published_at":"2026-09-03T00:30:00.430Z","article_body":"Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain\n\nPR Newswire\n\nCAMBRIDGE, Mass., Sept. 2, 2026\n\nCAMBRIDGE, Mass., Sept. 2, 2026 /PRNewswire/ -- Insilico Medicine (\"Insilico\",\nHKEX: 3696), a clinical-stage drug discovery company powered by generative\nartificial intelligence (AI), announced that it will be included in the HKEX\nTech 100 Index, following the methodology enhancements to broaden the exposure\nto \"emerging technology trends, including opportunities across the AI value\nchain\", announced on 18 August 2026. All changes will be implemented after the\nmarket close on 11 September 2026 (Friday) and take effect on 14 September\n2026 (Monday).\n\nThe HKEX Tech 100 Index is designed to measure the performance of 100 of the\nlargest Hong Kong-listed companies with high exposure to key tech themes, that\nare eligible for Southbound Stock Connect, addressing growing market demand\nfor diversified exposure to the technology sector. The benchmark focuses on\nthe nature of core business, revenue distribution and industry classification\nfor constituent evaluation, and covers both leading and emerging companies,\nspanning six themes, including artificial intelligence, biotech &\npharmaceutical, electric vehicles & smart driving, information technology,\ninternet and robotics.\n\nFor Insilico Medicine, inclusion in the HKEX Tech 100 Index provides another\nsolid proof of its AI technology capabilities and generative AI-driven\nadvancements in healthcare. In addition to validating the company's\ntechnological strength, the inclusion is expected to enhance trading liquidity\nand expand capital access. With the index serving as a key benchmark for\ntech-focused portfolios and linking directly to Southbound Stock Connect, this\nis expected to drive steady inflows from index-tracking passive funds and\nMainland Chinese investors. Ultimately, it broadens the stock's shareholder\nbase, and strengthens its visibility among Hong Kong-listed tech equities.\n\nPreviously, Insilico Medicine has been included into several major index\nseries, including MSCI Global Small Cap Indexes, the China Securities Index\n(CSI) Series (CSI Hong Kong Connect Innovative Drug Index, CSI Hong Kong Brand\nName Drug Index, and CSI HK Connect Health Care Composite Index), Hang Seng\nComposite Index, Hang Seng Healthcare Index, Hang Seng Biotechnology Index,\nFTSE Global Small Cap Index, FTSE Global All-Cap Index, and FTSE Global\nTotal-Cap Index.\n\nRecently, Insilico reported total revenue of approximately $106 million in the\nfirst half of 2026, a 287% year-over-year increase, and achieved its first\nprofitable half-year since listing, with an adjusted net profit exceeding $51\nmillion. This milestone was driven by a series of out-licensing,\nco-development, and R&D collaborations with global partners, including Eli\nLilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia\nTherapeutics, CMS, and Tenacia. As of the latest practicable date, the total\ncontract value of transactions announced by Insilico in 2026 reached\napproximately $7.3 billion, pushing the cumulative contract value of its major\ncollaborations since 2021 approximately $11 billion.\n\nOn the AI-driven R&D front, Insilico nominated nine development candidates\nwithin nine months of 2026 as of late August, setting a new company record for\nannual pipeline productivity and achieving eight clinical milestones across\nits proprietary and co-developed programs. Leading this progress is\nRentosertib (ISM001-055), the world's first drug candidate discovered and\ndeveloped using generative AI, which has advanced to a Phase III trial\nevaluating for idiopathic pulmonary fibrosis (IPF).\n\nAbout Insilico Medicine\n\nInsilico Medicine is a pioneering global biotechnology company dedicated to\nintegrating artificial intelligence and automation technologies to accelerate\ndrug discovery, drive innovation in the life sciences, and extend healthy\nlongevity to people on the planet. The company was listed on the Main Board of\nthe Hong Kong Stock Exchange on December 30, 2025, under the stock code\n03696.HK.\n\nBy integrating AI and automation technologies and deep in-house drug discovery\ncapabilities, Insilico is delivering innovative drug solutions for unmet needs\nincluding fibrosis, oncology, immunology, pain, and obesity and metabolic\ndisorders. Additionally, Insilico extends the reach of Pharma. AI across\ndiverse industries, such as advanced materials, agriculture, nutritional\nproducts and veterinary medicine.\n\nFor more information, please visit www.insilico.com\n(https://www.insilico.com/)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/insilico-medicine-included-in-the-hkex-tech-100-index-drawing-attention-to-opportunities-in-ai-value-chain-302867744.html\n(https://www.prnewswire.com/news-releases/insilico-medicine-included-in-the-hkex-tech-100-index-drawing-attention-to-opportunities-in-ai-value-chain-302867744.html)\n\nSOURCE Insilico Medicine\n\n\n\nJoy Hu, joy@insilico.ai, +86-13818050383\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn3J2XFJa","title":"Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain","author":"PR Newswire","ticker":"3696","created":"2026-09-03T00:30:00.430Z","tickers":["3696"],"exchange":"HKEX","article_body":"Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain\n\nPR Newswire\n\nCAMBRIDGE, Mass., Sept. 2, 2026\n\nCAMBRIDGE, Mass., Sept. 2, 2026 /PRNewswire/ -- Insilico Medicine (\"Insilico\",\nHKEX: 3696), a clinical-stage drug discovery company powered by generative\nartificial intelligence (AI), announced that it will be included in the HKEX\nTech 100 Index, following the methodology enhancements to broaden the exposure\nto \"emerging technology trends, including opportunities across the AI value\nchain\", announced on 18 August 2026. All changes will be implemented after the\nmarket close on 11 September 2026 (Friday) and take effect on 14 September\n2026 (Monday).\n\nThe HKEX Tech 100 Index is designed to measure the performance of 100 of the\nlargest Hong Kong-listed companies with high exposure to key tech themes, that\nare eligible for Southbound Stock Connect, addressing growing market demand\nfor diversified exposure to the technology sector. The benchmark focuses on\nthe nature of core business, revenue distribution and industry classification\nfor constituent evaluation, and covers both leading and emerging companies,\nspanning six themes, including artificial intelligence, biotech &\npharmaceutical, electric vehicles & smart driving, information technology,\ninternet and robotics.\n\nFor Insilico Medicine, inclusion in the HKEX Tech 100 Index provides another\nsolid proof of its AI technology capabilities and generative AI-driven\nadvancements in healthcare. In addition to validating the company's\ntechnological strength, the inclusion is expected to enhance trading liquidity\nand expand capital access. With the index serving as a key benchmark for\ntech-focused portfolios and linking directly to Southbound Stock Connect, this\nis expected to drive steady inflows from index-tracking passive funds and\nMainland Chinese investors. Ultimately, it broadens the stock's shareholder\nbase, and strengthens its visibility among Hong Kong-listed tech equities.\n\nPreviously, Insilico Medicine has been included into several major index\nseries, including MSCI Global Small Cap Indexes, the China Securities Index\n(CSI) Series (CSI Hong Kong Connect Innovative Drug Index, CSI Hong Kong Brand\nName Drug Index, and CSI HK Connect Health Care Composite Index), Hang Seng\nComposite Index, Hang Seng Healthcare Index, Hang Seng Biotechnology Index,\nFTSE Global Small Cap Index, FTSE Global All-Cap Index, and FTSE Global\nTotal-Cap Index.\n\nRecently, Insilico reported total revenue of approximately $106 million in the\nfirst half of 2026, a 287% year-over-year increase, and achieved its first\nprofitable half-year since listing, with an adjusted net profit exceeding $51\nmillion. This milestone was driven by a series of out-licensing,\nco-development, and R&D collaborations with global partners, including Eli\nLilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia\nTherapeutics, CMS, and Tenacia. As of the latest practicable date, the total\ncontract value of transactions announced by Insilico in 2026 reached\napproximately $7.3 billion, pushing the cumulative contract value of its major\ncollaborations since 2021 approximately $11 billion.\n\nOn the AI-driven R&D front, Insilico nominated nine development candidates\nwithin nine months of 2026 as of late August, setting a new company record for\nannual pipeline productivity and achieving eight clinical milestones across\nits proprietary and co-developed programs. Leading this progress is\nRentosertib (ISM001-055), the world's first drug candidate discovered and\ndeveloped using generative AI, which has advanced to a Phase III trial\nevaluating for idiopathic pulmonary fibrosis (IPF).\n\nAbout Insilico Medicine\n\nInsilico Medicine is a pioneering global biotechnology company dedicated to\nintegrating artificial intelligence and automation technologies to accelerate\ndrug discovery, drive innovation in the life sciences, and extend healthy\nlongevity to people on the planet. The company was listed on the Main Board of\nthe Hong Kong Stock Exchange on December 30, 2025, under the stock code\n03696.HK.\n\nBy integrating AI and automation technologies and deep in-house drug discovery\ncapabilities, Insilico is delivering innovative drug solutions for unmet needs\nincluding fibrosis, oncology, immunology, pain, and obesity and metabolic\ndisorders. Additionally, Insilico extends the reach of Pharma. AI across\ndiverse industries, such as advanced materials, agriculture, nutritional\nproducts and veterinary medicine.\n\nFor more information, please visit www.insilico.com\n(https://www.insilico.com/)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/insilico-medicine-included-in-the-hkex-tech-100-index-drawing-attention-to-opportunities-in-ai-value-chain-302867744.html\n(https://www.prnewswire.com/news-releases/insilico-medicine-included-in-the-hkex-tech-100-index-drawing-attention-to-opportunities-in-ai-value-chain-302867744.html)\n\nSOURCE Insilico Medicine\n\n\n\nJoy Hu, joy@insilico.ai, +86-13818050383\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-03T00:30:00.479808428Z","server_sent_at_ms":1788395400479},"received_at":"2026-09-03T00:30:00.539Z","source_url":"https://www.prnewswire.com/news-releases/insilico-medicine-included-in-the-hkex-tech-100-index-drawing-attention-to-opportunities-in-ai-value-chain-302867744.html"},"analysis":{"id":"123448","press_release_id":"134558","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["H1 2026 revenue growth (+287% YoY) is driven by out-licensing and co-development deal payments rather than product sales -- revenue is lumpy and milestone-dependent","Profitability is on an adjusted (non-IFRS) basis; statutory profitability is not stated","Company listed on HKEX only on December 30, 2025 -- short public trading history"],"eventType":"other","narrative":"Insilico Medicine (HKEX: 3696) will be added to the HKEX Tech 100 Index following the index's August 18 methodology enhancements broadening exposure to the AI value chain, with changes implemented after the close on September 11 and effective September 14, 2026.\n\nThe inclusion ties the stock to a benchmark for tech-focused portfolios eligible for Southbound Stock Connect, and the company expects it to enhance trading liquidity, drive inflows from index-tracking passive funds and Mainland Chinese investors, and broaden the shareholder base.\n\nIt caps a strong first year after the December 30, 2025 listing: H1 2026 revenue was approximately $106 million, up 287% year-over-year, with the first profitable half since listing on adjusted net profit exceeding $51 million, driven by out-licensing and co-development deals with partners including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals and Qilu Pharmaceutical; 2026 announced deal contract value reached roughly $7.3 billion of an ~$11 billion cumulative total since 2021.\n\nOn the pipeline, Insilico nominated nine development candidates in nine months of 2026 and logged eight clinical milestones, led by Rentosertib (ISM001-055), the world's first drug candidate discovered and developed with generative AI, now in a Phase III trial for idiopathic pulmonary fibrosis.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"HKEX Tech 100 inclusion opens a passive-inflow channel via Southbound Stock Connect for the newly listed AI drug-discovery name."},"keyFigures":{"revenue":106000000,"revenueYoy":"287%","customDimensions":{"adjusted_net_profit":">$51 million","contract_value_2026_usd":7300000000,"clinical_milestones_2026":8,"development_candidates_2026":9,"index_inclusion_effective_date":"2026-09-14","cumulative_contract_value_since_2021_usd":11000000000}},"quotedText":"the inclusion is expected to enhance trading liquidity","namedEntities":{"people":[],"products":["Rentosertib (ISM001-055)","Pharma.AI"],"companies":[{"name":"Insilico Medicine","ticker":"3696","relationship":"filer (issuer)"},{"name":"Hong Kong Exchanges and Clearing (HKEX)","relationship":"index provider"},{"name":"Eli Lilly","relationship":"partner"},{"name":"Servier","relationship":"partner"},{"name":"Takeda","relationship":"partner"},{"name":"SK Biopharmaceuticals","relationship":"partner"},{"name":"Qilu Pharmaceutical","relationship":"partner"},{"name":"Hygtia Therapeutics","relationship":"partner"},{"name":"CMS","relationship":"partner"},{"name":"Tenacia","relationship":"partner"},{"name":"MSCI","relationship":"index provider (prior inclusion)"},{"name":"FTSE Russell","relationship":"index provider (prior inclusion)"},{"name":"Hang Seng Indexes","relationship":"index provider (prior inclusion)"},{"name":"China Securities Index (CSI)","relationship":"index provider (prior inclusion)"}],"dollarAmounts":[{"amount":"$106 million","context":"H1 2026 total revenue"},{"amount":"$51 million","context":"adjusted net profit, first profitable half-year since listing"},{"amount":"$7.3 billion","context":"total contract value of transactions announced by Insilico in 2026"},{"amount":"$11 billion","context":"cumulative contract value of major collaborations since 2021"}]},"materialImpact":{"score":3,"reasoning":"Index inclusion is a genuine liquidity catalyst for a newly listed name -- it links the stock to a benchmark eligible for Southbound Stock Connect and is expected to drive passive-fund inflows -- but it is not a binary, regulatory, or capital-structure event warranting a 4-5."},"tickerRelevance":{"others":[],"primary":"3696"},"globalImportance":32,"audienceRelevance":30,"eventTypeSecondary":["operations_update"],"importanceComponents":{"recentIPO":"listed 2025-12-30","tickerTier":"recently listed HK mid/small-cap","eventGravity":"index inclusion with passive-flow potential","sectorWeight":"AI-biotech crossover theme","issuerAuthored":true,"retailFavoriteBoost":"AI drug-discovery narrative, first generative-AI-discovered drug in Phase III"}},"event_type":"other","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Insilico Medicine (HKEX: 3696) will be added to the HKEX Tech 100 Index following the index's August 18 methodology enhancements broadening exposure to the AI value chain, with changes implemented after the close on September 11 and effective September 14, 2026.\n\nThe inclusion ties the stock to a benchmark for tech-focused portfolios eligible for Southbound Stock Connect, and the company expects it to enhance trading liquidity, drive inflows from index-tracking passive funds and Mainland Chinese investors, and broaden the shareholder base.\n\nIt caps a strong first year after the December 30, 2025 listing: H1 2026 revenue was approximately $106 million, up 287% year-over-year, with the first profitable half since listing on adjusted net profit exceeding $51 million, driven by out-licensing and co-development deals with partners including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals and Qilu Pharmaceutical; 2026 announced deal contract value reached roughly $7.3 billion of an ~$11 billion cumulative total since 2021.\n\nOn the pipeline, Insilico nominated nine development candidates in nine months of 2026 and logged eight clinical milestones, led by Rentosertib (ISM001-055), the world's first drug candidate discovered and developed with generative AI, now in a Phase III trial for idiopathic pulmonary fibrosis.","key_figures":{"revenue":106000000,"revenueYoy":"287%","customDimensions":{"adjusted_net_profit":">$51 million","contract_value_2026_usd":7300000000,"clinical_milestones_2026":8,"development_candidates_2026":9,"index_inclusion_effective_date":"2026-09-14","cumulative_contract_value_since_2021_usd":11000000000}},"named_entities":{"people":[],"products":["Rentosertib (ISM001-055)","Pharma.AI"],"companies":[{"name":"Insilico Medicine","ticker":"3696","relationship":"filer (issuer)"},{"name":"Hong Kong Exchanges and Clearing (HKEX)","relationship":"index provider"},{"name":"Eli Lilly","relationship":"partner"},{"name":"Servier","relationship":"partner"},{"name":"Takeda","relationship":"partner"},{"name":"SK Biopharmaceuticals","relationship":"partner"},{"name":"Qilu Pharmaceutical","relationship":"partner"},{"name":"Hygtia Therapeutics","relationship":"partner"},{"name":"CMS","relationship":"partner"},{"name":"Tenacia","relationship":"partner"},{"name":"MSCI","relationship":"index provider (prior inclusion)"},{"name":"FTSE Russell","relationship":"index provider (prior inclusion)"},{"name":"Hang Seng Indexes","relationship":"index provider (prior inclusion)"},{"name":"China Securities Index (CSI)","relationship":"index provider (prior inclusion)"}],"dollarAmounts":[{"amount":"$106 million","context":"H1 2026 total revenue"},{"amount":"$51 million","context":"adjusted net profit, first profitable half-year since listing"},{"amount":"$7.3 billion","context":"total contract value of transactions announced by Insilico in 2026"},{"amount":"$11 billion","context":"cumulative contract value of major collaborations since 2021"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-03T00:32:01.707Z","global_importance":32,"audience_relevance":30,"importance_components":{"recentIPO":"listed 2025-12-30","tickerTier":"recently listed HK mid/small-cap","eventGravity":"index inclusion with passive-flow potential","sectorWeight":"AI-biotech crossover theme","issuerAuthored":true,"retailFavoriteBoost":"AI drug-discovery narrative, first generative-AI-discovered drug in Phase III"}},"durationMs":121160,"modelName":"glm-4.7"}}